Nearly 30 Percent of Adults Surveyed Don’t Think GERD is Common, Says a New Poll Released for GERD Awareness Week

Share Article Outlines Information About GERD

Get to know GERD, or gastroesophageal reflux disease, at, a website released for GERD Awareness Week (November 21-27, 2010). GERD is commonly known as acid reflux disease. Approximately 80 percent of people recently polled* were not aware that GERD affects nearly 19 million Americans.

GERD is often a chronic condition characterized by frequent and persistent heartburn. People who experience heartburn two or more days a week despite treatment and diet changes could have GERD. Individuals with GERD should talk to a health care professional about ways to manage their symptoms. DEXILANT™ (dexlansoprazole), a prescription medication, could be an option for appropriate patients.

“Even though GERD affects nearly 19 million Americans, many patients who come to me do not know that their frequent heartburn and other related symptoms are being caused by GERD,” said Dr. David Johnson, professor of medicine and chief of gastroenterology at Eastern Virginia School of Medicine. “GERD-related symptoms can be triggered by certain foods, stress, or pressure on the stomach. It’s especially important for patients with GERD to be aware of their triggers. This is highlighted during GERD Awareness Week – a time to remind patients with GERD to avoid their trigger foods and manage stress during the holiday season.”

“As a doctor who treats people with GERD every day, I know firsthand that lifestyle modifications can help manage heartburn related to GERD. However, if these changes don't help to relieve symptoms, a doctor may recommend treatment with medication,” noted Dr. Johnson.

*Results from findings of Omnibus telephone poll of 1,000 U.S. adults conducted in October 2010.

About DEXILANT™ (dexlansoprazole) 30 mg and 60 mg delayed release capsules
DEXILANT is a proton pump inhibitor (PPI), which decreases acid production by turning off many of the acid pumps in the stomach, thus helping to protect the esophagus from acidic reflux so that esophageal inflammation can heal. DEXILANT combines an enantiomer of lansoprazole with a Dual Delayed Release™ (DDR) formulation designed to provide two separate releases of medication. DEXILANT, taken once daily, is approved for the healing of all grades of erosive esophagitis (EE) for up to eight weeks, maintaining healing of EE for up to six months, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.

Important Safety Information
DEXILANT is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity and anaphylaxis have been reported with DEXILANT use. Symptomatic response with DEXILANT does not preclude the presence of gastric malignancy. Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. The most commonly reported treatment-emergent adverse reactions include diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory tract infection (1.9%), vomiting (1.6%), and flatulence (1.6%). DEXILANT must not be co-administered with atazanavir because atazanavir systemic concentrations may be substantially decreased. DEXILANT may interfere with the absorption of drugs for which gastric pH is important for bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole). Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Concomitant tacrolimus use may increase tacrolimus whole blood concentrations.

Please click here for full prescribing information and visit the DEXILANT Web site at

Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.
Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, gastroenterology, neurology and other conditions. To learn more about these Takeda companies, visit

For more information and tips about GERD, and to learn about DEXILANT, visit


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Amy Losak

Email >
Visit website